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Supplementary Figure S1:
Fig. S1. IgM and IgG antibody induction to individual merozoite antigens following primary P. falciparum infection in naïve adults. (A) IgM reactivity to non-malarial protein BSA was tested before (day 0) and after CHMI (day 30), n=40. There was no increase in nonimmune IgM following CHMI. A subset of samples are shown individually in right panel.
(B/C) IgM (B) and IgG (C) responses to a number of merozoite antigens were assessed at day 30 following infection and compared to day 0 responses prior to infection. Samples used were from the controlled human malaria infection model (n=20). were assessed in children and adults during clinical malaria, and at 7 and 28 days after treatment (day 7 children n=14, adults n=12, day 28 children n= 8, adults n=24). Data is ELISA OD. IgM (10g/ml) or IgG (100g/ml) was incubated with GFP +ve merozoitesand 25% normal sera. Samples were analysed by flow cytometry and GFP+ merozoites assessed over time. Data is expressed as a % of GFP +ve merozoites at 1 minute in control sample. Control is merozoites incubated in heatinactivated sera. 
